– USA, CA – ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the election of Dr. David Wheadon (M.D.) to its Board as an independent director, effective May 26, 2022.
The company also announced the retirement of Dr. Henry McKinnell, Jr. from the Board.
“Dr. David E. Wheadon adds strength and depth to our Board,” said CEO, Dr. Tom Schall. “We look forward to benefitting from his extensive knowledge in science, clinical, and regulatory affairs as we seek to expand TAVNEOS’s commercial and clinical activities, advance our novel small molecule checkpoint inhibitor, CCX559, for the treatment of cancer, and bring additional pipeline assets to patients in need.”
About Dr. David E. Wheadon
Dr. Wheadon retired from AstraZeneca PLC in 2019 as SVP, Global Regulatory Affairs, Patient Safety, and Quality Assurance, a position he had held since 2014. Before joining AstraZeneca, Dr. Wheadon held a variety of leadership roles in the healthcare sector, including EVP, Research, and Advocacy at the Juvenile Diabetes Research Foundation, SVP of Global Pharmaceutical Regulatory and Medical Sciences at Abbott Laboratories, and SVP of U.S. Regulatory Affairs at GlaxoSmithKline Laboratories. Dr. Wheadon has also served as SVP, Scientific and Regulatory Affairs at PhRMA, the Washington D.C.-based Pharmaceutical Industry Research and Manufacturers Association, during which time he interacted with the Food and Drug Administration, the Department of Health and Human Services, and the National Institutes of Health.
“ChemoCentryx combines a passionate focus on unmet needs with proven expertise in drug discovery and development,” said Dr. Wheadon. “I look forward to working closely with my new colleagues in this rapidly growing organization to bring small molecule therapeutics to those who need it the most.”
Dr. Wheadon currently serves on the boards of Karuna Therapeutics Inc., Sotera Health Company, and Vaxart, Inc.
He holds an M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts.
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS, the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe hidradenitis suppurativa and C3 glomerulopathy. Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and cancer.
For more information: https://www.chemocentryx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.